ReviewWorld journal of gastroenterology2006
Pharmacogenetics in inflammatory bowel disease.
Review in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis.The Journal of investigative dermatology · 2012Pooled it
- Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.World journal of gastroenterology · 2010Pooled it
- Prevalence and outcome of anemia after restorative proctocolectomy: a clinical literature review.Diseases of the colon and rectum · 2009Pooled it
- Chronotherapy in Inflammatory Bowel Disease: Biological Rationale, Human Evidence, and a Clinical Implementation Framework.Digestive diseases and sciences · 2026Review
- Review
- Pharmacogenetic Analysis of theGenes · 2023Article
- Patients With IBD Receiving Methotrexate Are at Higher Risk of Liver Injury Compared With Patients With Non-IBD Diseases: A Meta-Analysis and Systematic Review.Frontiers in medicine · 2021Article
- NGS study of glucocorticoid response genes in inflammatory bowel disease patients.Archives of medical science : AMS · 2021Article
- Glucocorticoid receptor gene haplotype structure and steroid therapy outcome in IBD patients.World journal of gastroenterology · 2010Article
- IL-10 and TNF-alpha promoter haplotypes are associated with childhood Crohn's disease location.World journal of gastroenterology · 2009Article
- Distribution of TPMT risk alleles for thiopurine [correction of thioupurine] toxicity in the Israeli population.European journal of clinical pharmacology · 2009Article
- Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.Biologics : targets & therapy · 2008Article
- Gene polymorphisms and pharmacogenetics in rheumatoid arthritis.Current genomics · 2008Article
- Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease.World journal of gastroenterology · 2008Article
- Treatment of inflammatory bowel disease: a review of medical therapy.World journal of gastroenterology · 2008Review
- Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events.The Journal of molecular diagnostics : JMD · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenetics is the study of the association between variability in drug response and (or) drug toxicity and polymorphisms in genes. The goal of this field of science is to adapt drugs to a patient's specific genetic background and therefore make them more efficacious and safe. In this article we describe the variants in genes that influence either the efficacy or toxicity of common drugs used in the treatment of inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn's disease (CD) including sulfasalazine and mesalazine, azathioprine (AZA) and 6-mercaptopurine (6-MP), methotrexate (MTX), glucocorticosteroids (CSs) and infliximab. Furthermore, difficulties with pharmacogenetic studies in general and more specifically in IBD are described. Although pharmacogenetics is a promising field that already contributed to a better understanding of some of the underlying mechanisms of action of drugs used in IBD, the only discovery translated until now into daily practice is the relation between thiopurine S-methyltransferase (TPMT) gene polymorphisms and hematological toxicity of thiopurine treatment. In the future it is necessary to organize studies in well characterized patient cohorts who have been uniformly treated and systematically evaluated in order to quantitate drug response more objectively. An effort should be made to collect genomic DNA from all patients enrolled in clinical drug trials after appropriate informed consent for pharmacogenetic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.